Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
Rhea-AI Summary
Nona Biosciences and Atossa Therapeutics (Nasdaq: ATOS) have announced a research collaboration to develop next-generation therapeutic antibodies for breast cancer. The partnership will utilize Nona's proprietary H2L2 Harbour Mice® platform, which generates fully human monoclonal antibodies without requiring additional engineering or humanization.
The platform combines transgenic mice technology with single B cell cloning, offering an efficient approach to therapeutic antibody development. The Harbour Mice® platform has been implemented in over 250 drug discovery programs across multiple therapeutic areas and has gained widespread recognition from global partners.
Positive
- Strategic partnership to develop novel breast cancer therapies
- Access to proven Harbour Mice® platform with track record of 250+ drug discovery programs
- Technology eliminates need for additional antibody engineering, potentially accelerating development timeline
Negative
- Early-stage research collaboration with no guaranteed success
- No specific timeline or financial terms disclosed
News Market Reaction
On the day this news was published, ATOS declined 4.90%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Nona Biosciences' proprietary Harbour Mice® platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and accelerating drug discovery and development. To date, Harbour Mice® platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas and has been widely recognized by global partners.
"We are pleased to collaborate with Atossa Therapeutics to discover next-generation antibody therapies for breast cancer," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. "This partnership highlights the value of our proprietary Harbour Mice® platform and reflects the industry's growing demand for innovative antibody discovery solutions. With Nona's industry-leading technology and expertise, we look forward to supporting Atossa's exploration of antibody-based approaches within their oncology pipeline."
About Nona Biosciences
Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to ITM"), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.
Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: www.nonabio.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer-302425464.html
SOURCE Nona Biosciences
FAQ
What is the purpose of the collaboration between Nona Biosciences and Atossa Therapeutics (ATOS)?
How does the Harbour Mice® platform used in ATOS collaboration work?
How many drug discovery programs has the Harbour Mice® platform been used in?
What specific technology will ATOS use in this breast cancer research collaboration?
